Effect of use of oral antiviral agents on reducing critical illness and mortality for patients with moderate to severe COVID-19 - Vienna 2024

Developing and assessing treatments for respiratory infection

Chair(s): Sara Bonvini, Martin Witzenrath

Session type: Poster session

Effect of use of oral antiviral agents on reducing critical illness and mortality for patients with moderate to severe COVID-19

Zhao Jun Jin

EVENTS HOME

Abstract

Previous presentation

Next presentation

Session content

Risk factors for adverse events of trimethoprim-sulfamethoxazole treatment in patients with non-HIV-PCP: a multi-centre, retrospective observational cohort study

Reina Idemitsu

Poster

Abstract

Advanced in vitro and ex vivo models provide a suitable platform for the evaluation of antiviral small molecules against human parainfluenza virus 3

Fabian R?pken

Poster

Abstract

Impact of saline solutions nebulisation on the biophysical properties of sputum in bronchiectasis

Victoria Alcaraz-serrano

Poster

Abstract

Inhaled colistimethate sodium in adult bronchiectasis patients with new asymptomatic Pseudomonas aeruginosa infection an open-label, proof of concept- randomized controlled trial (ERADICATE)

Pontus Mertsch

Abstract

Erdosteine inhibits viral infection and modulates innate immunity and stress oxidative state in RSV-infected A549 cell

Pierachille Santus

Poster

Abstract

Predictive factors of intolerance to nebulized antibiotics. A multicentre retrospective cohort study (Inbreathing study)

Carlos Manzano Senra

Poster

Abstract

Antiviral RNAi inhalation inhibits human parainfluenza infection ex vivo and in vivo

Philippe Vollmer Barbosa

Abstract

Experience of Eliava Phage Therapy Center in the treatment of respiratory infections

Mariam Dadiani

Abstract

Allicin can effectively treat Aspergillus fumigatus by inhibiting the germination of conidia via oxidative stress.

Zhengtu Li

Abstract

Comparison of the effectiveness of Simnotrelvir/Ritonavir and Nirmatrelvir/Ritonavir in the treatment of COVID-19 moderate hospitalized patients with severe high-risk factors

Yu Ting Zhang

Abstract

Quality of life in adult bronchiectasis treated with long-term High flow therapy

Francesca Simioli

Poster

Abstract

Changes in antibiotic therapy are associated with increased morbidity and mortality in community-acquired pneumonia: Insights from CAPNETZ

Julius Kohlh?ufl

Poster

Abstract

Effectiveness of Prolonged Awake Prone Positioning in Preventing Intubation among Less Severely Patients with COVID-19-Related Acute Hypoxemic Respiratory Failure

Lietao Wang

Abstract

Prognostic implications of cluster analysis in patients with chronic bronchial infection under nebulized antibiotic therapy: A multicentre retrospective cohort study (INBREATHING STUDY)

Beatriz Raboso Moreno

Poster

Abstract

Non-invasive ventilation in the management of bronchiectasis

Rachel Dexter-spooncer

Poster

Abstract

Lack of diversity and socioeconomic inclusions in clinical trial protocols for long-term antibiotics in bronchiectasis: a systematic review

Natasha Smallwood

Poster

Abstract

Effect of use of oral antiviral agents on reducing critical illness and mortality for patients with moderate to severe COVID-19

Zhao Jun Jin

Abstract

The comparison of outcomes in community-acquired pneumonia treated azithromycin or doxycycline in combination with beta-lactams: A cohort study

Yewande Odeyemi

Poster

Abstract

CDN Connection Issue

The ERS Congress 2024, Vienna

#{title}